Ńjẹ́rìísi...
A túmọ̀ rẹ̀ láìfọwọ́yí. Fún ìwọ̀n oògùn àti ìkìlọ̀: wo ẹ̀dà Gẹ̀ẹ́sì àkọ́kọ́. Ka ní Gẹ̀ẹ́sì

Allopurinol Tablets

NAFDAC Reg. Rárá. A4-5688 · Oògùn

Forukọsilẹ pẹlu NAFDAC. Iforukọsilẹ ti nṣiṣe lọwọAs of 5 November 2026 · synced automatically from official sources.
Ọja
Allopurinol Tablets
Nọmba NAFDAC
A4-5688
Ohun elo ti nṣiṣe lọwọ
Allopurinol
Agbara
100 mg
Fọọmu
Tablet
Iwọn iṣakojọpọ
10 x 10's (in blisters)
Olupese
Ko ṣe atokọ
Olubẹwẹ (oluranlowo)
Dony-Triumph and Company Nigeria Limited
Ti fọwọsi
6 Jul 2023
Ipò
Nṣiṣẹ Wo lórí NAFDAC ↗
Iforukọsilẹ wulo si
5 Jul 2028
Tani o ṣe itaniji
Kosi ikankan ti a rii.
Ijabọ Agbegbe
Kò sí
Àwọn àyẹ̀wò àsìkò
0

Nipa oogun naa: Allopurinol: uses, dosage and brands worldwide

What we found

  • Allopurinol Tablets is on the NAFDAC register with an active registration (A4-5688). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Allopurinol Tablets

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Tani o jẹ fun

Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and i …

Bii o ṣe le mu u ati igba melo ni
  • Gout : Prior to initiating treatment assess serum uric acid level, complete blood count, chemistry panel, liver and kidney function tests
  • Prophylactic treatment for gout flares is recommended
  • Patients with normal kidney function: Initial dosage is 100 mg orally daily
  • Increase by 100 mg weekly increments until serum uric acid of 6 mg/dl or less is reached (maximum 800 mg daily)
  • Patients with impaired kidney function: The initial dosage is 50 mg orally daily
  • Follow recommendations for titration in patients with renal impairment until target serum uric acid level is reached
  • See complete information in the Full Prescribing Information (FPI)
  • Hyperuricemia Associated with Cancer Therapy : The recommended dosage is: Adults: 300 mg to 800 mg orally daily
  • Pediatric patients: 100 mg/m 2 orally every 8 hours to 12 hours (10 mg/kg/day, maximum 800 mg/day) See complete information in the FPI
  • Recurrent Calcium Oxalate Calculi : The recommended initial dosage in patients with normal kidney function is 200 mg to 300 mg orally daily
  • Dosage in Patients with Renal Impairment: See FPI for dosage modifications in patients with renal impairment. …
Strengths it comes in

Allopurinol tablets, USP have functional scoring and are available in the following strengths: 100 mg: White, round, flat face, beveled edge tablets. The upper layer is bisected and debossed with “2083/V”. The lower layer is plain. 300 mg: Orange, round and biconvex tablets. The upper layer is bisected and debossed with “2084/V”. The lower layer is plain. …

Children
  • Hyperuricemia Associated with Cancer Therapy The safety and effectiveness of allopurinol for the management of pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels have been established in approximately 200
  • Pediatric patients
  • The efficacy and safety profile observed in this patient population were similar to that observed
  • In adults. …
While you are taking it
  • Administration Advise patients to take allopurinol tablets after meals to minimize gastric irritation
  • If a single dose of allopurinol tablets is occasionally forgotten, there is no need to double the dose at the next scheduled time
  • Skin Rash and Hypersensitivity Inform patients that allopurinol tablets may increase the risk of serious and sometimes fatal dermatologic reactions. …
Talk to a doctor first if
  • Allopurinol tablets are contraindicated in patients with a history of hypersensitivity reaction to allopurinol or to any of the ingredients of allopurinol tablets
  • Known hypersensitivity to allopurinol or to any of the ingredients of allopurinol tablets
Medicines it may not mix with

The following drugs may increase the risk of serious skin reactions: bendamustine, thiazide diuretics, ampicillin and amoxicillin. ( 7.1 ) Capecitabine: Avoid concomitant use. ( 7.2 ) Mercaptopurine or Azathioprine: Reduce mercaptopurine or azathioprine dose as recommended in the respective prescribing information. ( 7.2 ) Pegloticase: Discontinue and refrain from initiating treatment with allopurinol tablets. ( 7.2 ) See FPI for complete list of significant drug interactions. …

Warnings

Skin Rash and Hypersensitivity: Allopurinol has been associated with serious and sometimes fatal dermatological reactions. Discontinue allopurinol tablets at the first appearance of skin rash or other signs of hypersensitivity reaction. ( 5.1 ) Gout Flares: May occur during initiation of treatment. Concurrent prophylactic treatment with colchicine or anti-inflammatory agents is recommended. ( 5.2 ) Nephrotoxicity: Allopurinol may affect kidney function. Patients with decreased kidney function require lower doses of allopurinol tablets. ( 5.3 ) Hepatoxicity: Cases of reversible hepatotoxicity have occurred. If signs and symptoms of hepatotoxicity develop, evaluate liver function. …

Àbájáde tí ó ṣeéṣe

The following clinically significant adverse reactions are described elsewhere in the labeling: Skin Rash and Hypersensitivity [see Warnings and Precautions ( 5.1 )] Nephrotoxicity [see Warnings and Precautions ( 5.3 )] Hepatoxicity [see Warnings and Precautions ( 5.4 )] Myelosuppression [see Warnings and Precautions ( 5.5 )] Potential Effect on Driving and Use of Machinery [see Warnings and Precautions ( 5.6 )] The following adverse reactions associated with the use of allopurinol tablets were identified in literature, unpublished clinical trials or postmarketing reports. …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary Based on findings in animals, allopurinol tablets may cause fetal harm when administered to a pregnant woman. Adverse developmental outcomes have been described in exposed animals (see Data). Allopurinol and its metabolite oxypurinol have been shown to cross the placenta following administration of maternal allopurinol. …

If you take too much

In the management of overdosage there is no specific antidote for allopurinol tablets. Both allopurinol tablets and oxipurinol are dialyzable; however, the usefulness of hemodialysis or peritoneal dialysis in the management of an overdose of allopurinol tablets is unknown.

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2024-07-08.

Label for allopurinol, the active ingredient registered with NAFDAC.

Check your pack of Allopurinol Tablets

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Allopurinol Tablets

What is in Allopurinol Tablets?

Allopurinol Tablets contains Allopurinol (100 mg), as tablet, according to its NAFDAC registration record.

Is Allopurinol Tablets registered with NAFDAC?

Yes. Allopurinol Tablets is listed on the NAFDAC register under registration number A4-5688, and its registration is active as of 5 November 2026.

Has Allopurinol Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Allopurinol Tablets in our automatically synced alert list.

How can I check that my pack of Allopurinol Tablets is genuine?

Run a free authenticity scan with the NAFDAC number A4-5688, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Allopurinol Tablets?

Follow your prescription or the leaflet in your pack. The official label says: Gout : Prior to initiating treatment assess serum uric acid level, complete blood count, chemistry panel, liver and kidney function tests. Prophylactic treatment for gout flares is recommended. ( 2.1 , 2.2 ) Patients with normal kidney function: Initial dosage is 100 mg orally daily. Increase by 100 mg weekly increments until serum uric acid of 6 mg/dl or less is reached (maxim…

What is Allopurinol Tablets used for?

Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The m (Summarised from the official U.S. FDA label for allopurinol. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Allopurinol Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.